Free HLA typing for children with thalassaemia launched in India

The initiative by DKMS Foundation India is for below 12 years children suffering from transfusion-dependent thalassemia

Merck completes $5.8 billion acquisition of Terns Pharma

At the center of the deal is TERN-701, a drug recently granted Breakthrough Therapy Designation by the U.S. Food and Drug Administration for adults with Philadelphia chromosome-positive chronic myeloid leukemia

CARBOGEN AMCIS Shanghai site clears unannounced NMPA GMP inspection

Successful inspection outcome strengthens company’s regulatory compliance and manufacturing standards in China

Safic-Alcan expands in India with majority stake in SA Ingredients

The deal brings SAI — a key distributor serving pharmaceutical and nutraceutical manufacturers — into the Safic-Alcan Group’s expanding Asia footprint

GIMS Greater Noida expands paediatric orthopaedic care under Healthium's CSR initiative

Supported by Plan International, the partnership will help treat over 1,000 children annually

Lilly’s Omvoh shows rare long-term remission milestone in ulcerative colitis

Laurus Labs Q4 profit rises to Rs. 279 crore, FY26 revenue up 23%

The company reported robust revenue and profit growth for FY26, supported by strong CDMO performance, improving margins, and expansion across advanced manufacturing platforms

Biocon Biologics receives 5 procedural observations after US FDA inspection at Bengaluru facility

The US FDA completed a pre-license inspection of Biocon Biologics’ biosimilars manufacturing site at Biocon Park between April 20 and April 29, 2026

Revvity tops Q1 estimates and unveils plans to exit China immunodiagnostics

The company also announced a major portfolio shift, planning to divest its Immunodiagnostics business in China, a unit that generated approximately 6% of its fiscal 2025 revenue

Pfizer powers ahead in 2026 with strong Q1 results as pipeline momentum builds

The pharmaceutical giant reported $14.5 billion in revenue, up 5% year-over-year, and reaffirmed its full-year outlook